To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
Clinical trial NCT06378242 · RECRUITING
Trial details
- NCT number
- NCT06378242
- Sponsor
- RemeGen Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-14
- Primary completion
- 2029-03-15
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.